JP2018520117A5 - - Google Patents

Download PDF

Info

Publication number
JP2018520117A5
JP2018520117A5 JP2017561821A JP2017561821A JP2018520117A5 JP 2018520117 A5 JP2018520117 A5 JP 2018520117A5 JP 2017561821 A JP2017561821 A JP 2017561821A JP 2017561821 A JP2017561821 A JP 2017561821A JP 2018520117 A5 JP2018520117 A5 JP 2018520117A5
Authority
JP
Japan
Prior art keywords
patient
composition according
composition
mutation
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017561821A
Other languages
English (en)
Japanese (ja)
Other versions
JP7258462B2 (ja
JP2018520117A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/034861 external-priority patent/WO2016196385A1/en
Publication of JP2018520117A publication Critical patent/JP2018520117A/ja
Publication of JP2018520117A5 publication Critical patent/JP2018520117A5/ja
Priority to JP2021108659A priority Critical patent/JP2021152076A/ja
Application granted granted Critical
Publication of JP7258462B2 publication Critical patent/JP7258462B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017561821A 2015-05-29 2016-05-27 B細胞悪性腫瘍の治療のためのセルデュラチニブ Active JP7258462B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021108659A JP2021152076A (ja) 2015-05-29 2021-06-30 B細胞悪性腫瘍の治療のためのセルデュラチニブ

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562168530P 2015-05-29 2015-05-29
US62/168,530 2015-05-29
US201562263582P 2015-12-04 2015-12-04
US62/263,582 2015-12-04
PCT/US2016/034861 WO2016196385A1 (en) 2015-05-29 2016-05-27 Cerdulatinib for the treatment of b-cell malignancies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021108659A Division JP2021152076A (ja) 2015-05-29 2021-06-30 B細胞悪性腫瘍の治療のためのセルデュラチニブ

Publications (3)

Publication Number Publication Date
JP2018520117A JP2018520117A (ja) 2018-07-26
JP2018520117A5 true JP2018520117A5 (cg-RX-API-DMAC7.html) 2019-06-20
JP7258462B2 JP7258462B2 (ja) 2023-04-17

Family

ID=57441822

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017561821A Active JP7258462B2 (ja) 2015-05-29 2016-05-27 B細胞悪性腫瘍の治療のためのセルデュラチニブ
JP2021108659A Pending JP2021152076A (ja) 2015-05-29 2021-06-30 B細胞悪性腫瘍の治療のためのセルデュラチニブ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021108659A Pending JP2021152076A (ja) 2015-05-29 2021-06-30 B細胞悪性腫瘍の治療のためのセルデュラチニブ

Country Status (9)

Country Link
US (2) US20180147203A1 (cg-RX-API-DMAC7.html)
EP (1) EP3302485B1 (cg-RX-API-DMAC7.html)
JP (2) JP7258462B2 (cg-RX-API-DMAC7.html)
KR (1) KR102613106B1 (cg-RX-API-DMAC7.html)
CN (1) CN107683139A (cg-RX-API-DMAC7.html)
AU (1) AU2016270658B2 (cg-RX-API-DMAC7.html)
CA (1) CA2987324C (cg-RX-API-DMAC7.html)
ES (1) ES2958412T3 (cg-RX-API-DMAC7.html)
WO (1) WO2016196385A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2913119T3 (es) 2015-08-12 2022-05-31 Portola Pharm Inc Cerdulatinib para tratar mieloma
EP3383396B1 (en) 2015-12-04 2023-07-12 Alexion Pharmaceuticals, Inc. Cerdulatinib and venetoclax for treating non-hodgkin's lymphoma
US20180065317A1 (en) 2016-09-06 2018-03-08 Cc3D Llc Additive manufacturing system having in-situ fiber splicing
WO2018189566A1 (en) * 2017-04-10 2018-10-18 Dorian Bevec Use of a chemical compound as a therapeutic agent
KR20210003789A (ko) * 2018-05-04 2021-01-12 포톨라 파마슈티컬스, 인코포레이티드 림프종을 치료하는 방법
US10851087B2 (en) 2018-05-04 2020-12-01 Portola Pharmaceuticals, Inc. Synthesis of cerdulatinib
WO2019213606A2 (en) 2018-05-04 2019-11-07 Portola Pharmaceuticals, Inc. Solid forms of cerdulatinib
CN108743947B (zh) * 2018-07-04 2020-12-15 复旦大学附属肿瘤医院 一种治疗b细胞淋巴瘤的药物组合物
WO2021242614A1 (en) * 2020-05-26 2021-12-02 Alexion Pharmaceuticals, Inc. Circulating b cell subpopulations in indolent b cell lymphoma
EP4189080A4 (en) * 2020-07-26 2025-01-08 ASC Therapeutics Inc. CAS NUCLEASE VARIANTS

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60255756A (ja) 1984-06-01 1985-12-17 Ikeda Mohandou:Kk アミノアルキルフエノキシ誘導体
WO1995032963A1 (en) 1994-06-01 1995-12-07 Yoshitomi Pharmaceutical Industries, Ltd. Thienylazole compound and thienotriazolodiazepine compound
ATE401312T1 (de) 1997-12-15 2008-08-15 Astellas Pharma Inc Pyrimidin-5-carboxamid-derivate
WO2003037352A1 (en) 2001-11-02 2003-05-08 Pfizer Products Inc. 1-phenyl-5-n-heterocyclyl-pyrazoles as cyclooxygenase inhibitors for the treatment of inflammation associated disorders
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
ES2373226T3 (es) 2002-06-28 2012-02-01 Astellas Pharma Inc. Derivado de diaminopirimidincarboxamida.
WO2008009458A1 (en) 2006-07-21 2008-01-24 Novartis Ag 2, 4 -di (arylaminio) -pyrimidine-5-carboxamide compounds as jak kinases inhibitors
CA2723205C (en) 2008-04-16 2017-03-14 Portola Pharmaceuticals, Inc. 2,6-diamino-pyrimidin-5-yl-carboxamides as syk or jak kinase inhibitors
US8138339B2 (en) 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
WO2010129802A1 (en) 2009-05-06 2010-11-11 Portola Pharmaceuticals, Inc. Inhibitors of jak
WO2012045020A1 (en) 2010-09-30 2012-04-05 Portola Pharmaceuticals, Inc. Combinations of 4-(cyclopropylamino)-2-(4-(4-(ethylsulfonyl)piperazin-1-yl)phenylamino)pyrimidine-5-carboxamide and fludarabine
WO2013023119A1 (en) * 2011-08-10 2013-02-14 Novartis Pharma Ag JAK P13K/mTOR COMBINATION THERAPY
US20150368394A1 (en) * 2012-06-27 2015-12-24 Novomer, Inc. Catalysts and methods for polyester production
HK1206073A1 (en) * 2012-07-24 2015-12-31 药品循环有限责任公司 Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk)
WO2014058921A2 (en) 2012-10-08 2014-04-17 Portola Pharmaceuticals, Inc. Substituted pyrimidinyl kinase inhibitors
SG11201503459SA (en) 2012-11-02 2015-06-29 Pharmacyclics Inc Tec family kinase inhibitor adjuvant therapy
CN105282602A (zh) * 2014-07-07 2016-01-27 乐视致新电子科技(天津)有限公司 数据处理方法、装置及移动终端设备
EP3191098A4 (en) 2014-09-12 2018-04-25 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors
ES2913119T3 (es) 2015-08-12 2022-05-31 Portola Pharm Inc Cerdulatinib para tratar mieloma
EP3383396B1 (en) 2015-12-04 2023-07-12 Alexion Pharmaceuticals, Inc. Cerdulatinib and venetoclax for treating non-hodgkin's lymphoma

Similar Documents

Publication Publication Date Title
Xu et al. Current advances and future strategies for BCL-2 inhibitors: potent weapons against cancers
Matuszkiewicz-Rowinska et al. Prevention and treatment of tumor lysis syndrome in the era of onco-nephrology progress
Moskowitz et al. Targeting histone deacetylases in T-cell lymphoma
Lin et al. Immunomodulatory effects of current targeted therapies on hepatocellular carcinoma: implication for the future of immunotherapy
Kang et al. Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy
Löwenberg Sense and nonsense of high-dose cytarabine for acute myeloid leukemia
Shah et al. Vincristine sulfate liposomes injection (VSLI, Marqibo®): results from a phase I study in children, adolescents, and young adults with refractory solid tumors or leukemias
JP2018535996A5 (cg-RX-API-DMAC7.html)
RU2020114632A (ru) Терапевтические способы, относящиеся к ингибиторам hsp90
JP2018524347A5 (cg-RX-API-DMAC7.html)
JP2020510704A5 (cg-RX-API-DMAC7.html)
Kuczynski et al. Impact of chemical-induced mutational load increase on immune checkpoint therapy in poorly responsive murine tumors
CN108883109A (zh) 用于治疗急性髓性白血病的联合疗法
JP2021523114A5 (cg-RX-API-DMAC7.html)
JP2022532519A5 (cg-RX-API-DMAC7.html)
WO2011061222A1 (en) Therapeutic combination comprising a cdc7 inhibitor and an antineoplastic agent
Campbell et al. Antimyeloma effects of arsenic trioxide are enhanced by melphalan, bortezomib and ascorbic acid
Johnson‐Ansah et al. Tolerability and efficacy of pegylated interferon‐α‐2a in combination with imatinib for patients with chronic‐phase chronic myeloid leukemia
Mir et al. Drug-induced effects on erlotinib metabolism
Rajendra et al. Venetoclax: A narrative drug review
Lavenstein Treatment approaches for children with Tourette’s syndrome
JPH07506804A (ja) 痴呆の処置のためのダプソーン及びプロミン
Hochberg et al. Lymphoma in adolescents and young adults: current perspectives
Steinemann et al. Activity of nintedanib in germ cell tumors
Seiler et al. Advances in the management of follicular lymphoma